Kenya Launches Lenacapavir for Long-Term HIV Protection

Kenya has begun a new phase in its HIV prevention strategy with the introduction of Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP). The initiative, confirmed on February 17, 2026, marks Kenya as the first East African nation to implement this advanced prevention option.

The rollout is a collaboration between the Ministry of Health and the Global Fund, and aims to reduce new HIV infections among high-risk, HIV-negative populations.

Lenacapavir Mechanism and Usage

Lenacapavir functions by inhibiting the HIV-1 capsid protein, disrupting viral replication. It is administered as a subcutaneous injection every six months, maintaining protective drug levels. This contrasts with daily oral PrEP, addressing a common barrier to prevention success. It is important to note that Lenacapavir is intended for HIV-negative individuals at substantial risk and is not a treatment or vaccine. Routine HIV testing is required before each injection to prevent the development of drug resistance.

Rollout and Targeting

The implementation will proceed in phases, beginning in March 2026. Initially, 15 high-burden counties, identified through epidemiological surveillance, will be targeted. This phased approach allows for assessment of effectiveness, monitoring of adverse events, and evaluation of service delivery logistics before broader national implementation.

Advantages of Long-Acting Injectable PrEP

Long-acting injectable PrEP offers several operational advantages. These include reduced adherence challenges, increased discretion which may lower stigma, and improved continuity of protection for mobile or underserved populations. The strategy complements Kenya’s existing combination prevention framework, which includes barrier methods, testing services, and sexual health education.

Safety and Priority Groups

Healthcare providers will closely monitor safety through tracking injection-site reactions and other adverse events. The introduction of Lenacapavir reflects advancements in sustained-release drug delivery technology. Priority groups for this preventative measure include youth, sex workers, serodiscordant couples, and other high-transmission networks.

Potential Regional Impact and Success Metrics

Kenya’s early adoption of Lenacapavir may provide valuable insights for other regional health systems considering similar strategies. The success of the program will be evaluated based on lower infection rates, improved prevention coverage, and increased engagement in HIV prevention services.